04-30-08 Acura Pharmaceuticals, Inc. Reports Results for Q1-08

  04-24-08 King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal Phase III Clinical Trial Evaluating Acurox™

  03-24-08 Acura Pharmaceuticals, Inc. Names Robert B. Jones Chief Operating Officer

  03-05-08 Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations

  02-27-08 Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, to take Medical Leave and Appointment of Richard Markham as Chairman of the Board

  01-31-08 Acura Pharmaceuticals, Inc. Announces Approval To List Shares on NASDAQ and Effective Feb. 4, 2008, a New Trading Symbol: ACUR

  01-24-08 Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director

  12-10-07 Acura Pharmaceuticals, Inc. Announces Receipt of $30 Million Cash Payment and Closing of Agreement with King Pharmaceuticals

  12-04-07 Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH.OB

  11-02-07 Acura Pharmaceuticals, Inc. Reports Results for Q3-07

  10-31-07 King Pharmaceuticals and Acura Pharmaceuticals enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion® (Abuse-Deterrent) Technology

  10-31-07 Acura Pharmaceuticals, Inc. Announces Reverse Stock Split and Expected Payoff of $5 Million Secured Term Note

  08-20-07 Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion® Technology Product Candidate

  08-09-07 Acura Pharmaceuticals, Inc. Reports Results for Q2-07 and Cash Reserves

  07-10-07 Acura Pharmaceuticals, Inc. Secures Bridge Funding

  06-19-07 Acura Pharmaceuticals, Inc. and FDA Reach Agreement on Special Protocol Assessment for Pivotal Phase 3 Study for OxyADF Tablets

  05-18-07 Acura Pharmaceuticals, Inc. Completes Draw Down of March, 2007 Bridge Funding Commitment

  05-04-07 Acura Pharmaceuticals, Inc. Reports Results for Q1-07 and Cash Reserves

  04-16-07 Acura Pharmaceuticals, Inc. Announces Issuance of U.S. Patent for Deterring Abuse of Opioid Containing Dosage Forms

  04-02-07 Acura Pharmaceuticals, Inc. Secures Bridge Funding

  03-15-07 Acura Pharmaceuticals, Inc. Updates OxyADF Tablet Development Program and Results of Study AP-ADF-102

  03-15-07 Acura Pharmaceuticals, Inc. Reports 2006 Financial Results and Cash Reserves

  02-20-07 Acura Pharmaceuticals, Inc. Completes Draw Down of November 2006 Bridge Funding Commitment

  12-11-06 Acura Pharmaceuticals, Inc. Announces Notice of Allowance for Issuance of Patent for Deterring Abuse of Opioid Containing Dosage Forms